A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs FF 10501 (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors FujiFilm Pharmaceuticals USA; Strategia Therapeutics
- 16 Oct 2019 Status changed from active, no longer recruiting to completed.
- 29 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2019.
- 24 Jan 2019 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History